Skip to content
Advertisement

A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. Federal health advisers voted against an experimental treatment for Lou Gehrig’s disease at a Wednesday, Sept. 27, 2023, meeting prompted by years of patient efforts seeking access to the unproven therapy. (AP Photo/Jacquelyn Martin, File)

A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018. Federal health advisers voted against an experimental treatment for Lou Gehrig’s disease at a Wednesday, Sept. 27, 2023, meeting prompted by years of patient efforts seeking access to the unproven therapy. (AP Photo/Jacquelyn Martin, File)

Featured Photo Galleries